Characteristics of patients (n = 23)
| Variable . | Value . |
|---|---|
| Median (range) age, y | 44 (26-66) |
| Sex: M/F | 11/12 |
| Underlying disease | |
| CML | 5 |
| AML | 7 |
| ALL | 3 |
| Multiple myeloma | 5 |
| CLL | 2 |
| MDS | 1 |
| Patient/donor HCMV serologic status | |
| +/+ | 15 |
| −/+ | 3 |
| +/− | 5 |
| Source of stem cells | |
| Peripheral blood | 15 |
| Bone marrow | 7 |
| Bone marrow and peripheral blood | 1 |
| Conditioning regimen | |
| TBI/CY ± VP16 | 12 |
| BU/CY ± ARA-C | 5 |
| TBI/FLU/CY | 5 |
| TT/TNI | 1 |
| Type of donor | |
| HLA-identical sibling | 10 |
| Matched unrelated | 8 |
| Mismatched family member | 5 |
| GVHD prophylaxis | |
| CSA/ATG | 13 |
| CSA | 5 |
| CD34+selection*±CSA/ATG | 5 |
| Acute GVHD | |
| Grade 0/I | 13 |
| Grade II | 7 |
| Grade III/IV | 3 |
| Variable . | Value . |
|---|---|
| Median (range) age, y | 44 (26-66) |
| Sex: M/F | 11/12 |
| Underlying disease | |
| CML | 5 |
| AML | 7 |
| ALL | 3 |
| Multiple myeloma | 5 |
| CLL | 2 |
| MDS | 1 |
| Patient/donor HCMV serologic status | |
| +/+ | 15 |
| −/+ | 3 |
| +/− | 5 |
| Source of stem cells | |
| Peripheral blood | 15 |
| Bone marrow | 7 |
| Bone marrow and peripheral blood | 1 |
| Conditioning regimen | |
| TBI/CY ± VP16 | 12 |
| BU/CY ± ARA-C | 5 |
| TBI/FLU/CY | 5 |
| TT/TNI | 1 |
| Type of donor | |
| HLA-identical sibling | 10 |
| Matched unrelated | 8 |
| Mismatched family member | 5 |
| GVHD prophylaxis | |
| CSA/ATG | 13 |
| CSA | 5 |
| CD34+selection*±CSA/ATG | 5 |
| Acute GVHD | |
| Grade 0/I | 13 |
| Grade II | 7 |
| Grade III/IV | 3 |
Values are numbers of patients unless otherwise indicated. CML indicates chronic myeloid leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; HCMV, human cytomegalovirus; TBI, total body irradiation; CY, cyclophosphamide; VP16, etoposide; BU, busulfan; ARA-C, cytosine arabinoside; FLU, fludarabine; TT, thiotepa; TNI, total nodal irradiation; GVHD, graft-versus-host disease; CSA, cyclosporin A; and ATG, antithymocyte globulin.
CD34+ selection was performed by using the CliniMACS system.